Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF

In the September 17, 2024 issue of JACC, Valentin Fuster discusses a study on sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, which shows modest improvements in health status among patients with worsening heart failure. While the study highlights sotagliflozin's benefits, it also points out gaps in understanding its full impact and emphasizes the need to optimize current treatments and explore future interventions.